Actively Recruiting
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2025-11-20
24
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.
CONDITIONS
Official Title
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Confirmed diagnosis of relapsed or refractory malignant hematological tumors including B-ALL, B-cell lymphoma, or multiple myeloma
- ECOG performance status score between 0 and 2 with expected survival of at least 3 months
- Blood tests during screening must show hemoglobin ≥ 6 g/dL (without recent transfusion), absolute neutrophil count ≥ 600/µL, platelet count ≥ 50,000/µL, and lymphocyte count ≥ 500/µL
- Normal kidney function with creatinine clearance rate ≥ 45 mL/min
- Liver function within limits: ALT and AST ≤ 3 times upper limit, total bilirubin ≤ 2 times upper limit (with some exceptions)
- Heart function with left ventricular ejection fraction ≥ 40%, no significant pericardial effusion or ECG abnormalities
- Pulmonary function with blood oxygen saturation ≥ 90%
- Women of childbearing age must test negative for pregnancy and not be breastfeeding
- Men and women of childbearing potential must use effective contraception and not donate reproductive cells during and for 1 year after the study
- Signed informed consent form
You will not qualify if you...
- Received chemotherapy, targeted therapy, or immunotherapy within 5 half-lives before treatment
- Received radiotherapy within 4 weeks before treatment (unless small bone marrow area involved)
- Hematopoietic stem cell transplantation within 3 months before treatment
- History of other active malignant tumors within 2 years or untreated non-melanoma skin cancer
- Previous treatment with vesicular stomatitis virus glycoprotein pseudotyped virus
- Severe or uncontrolled infections during screening
- Significant cardiac diseases such as symptomatic heart failure, severe arrhythmia, recent heart attack or surgery, or severe cardiomyopathy
- Other serious diseases including primary immunodeficiency, recent stroke or seizure, dementia, Parkinson's disease or related disorders
- Surgery within 2 weeks before or planned within 2 weeks after treatment (except local anesthesia)
- Live attenuated vaccine received within 1 month before treatment
- History of severe allergic reactions to this therapy or its components
- Unsuitable for establishing intravenous access
- Any other condition deemed by the investigator as unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, China
Actively Recruiting
Research Team
W
Wang Sanbin, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here